Literature DB >> 20373027

TCR mispairing in genetically modified T cells was detected by fluorescence resonance energy transfer.

Hongwei Shao1, Wenfeng Zhang, Qinglian Hu, Fenglin Wu, Han Shen, Shulin Huang.   

Abstract

Adoptive transfer of T lymphocytes genetically modified with antigen-specific T cell receptor (TCR) constitutes a promising approach for the treatment of malignant tumors and virus infections. One of the challenges in this field of TCR gene therapy is TCR mispairing defining the incorrect pairing between an introduced TCR α or β chain and an endogenous TCR β or α chain, which results in diluted surface expression of the therapeutic TCR αβ. Although there is currently no clinical evidence for TCR mispairing-induced autoreactivity, the generation of autoreactive TCRs upon TCR mispairing cannot be excluded. So it is important to detect TCR mispairing to evaluate the efficiency of TCR gene therapy. Currently there is no available quantitative assay for the measurement of TCR mispairing. Fluorescence resonance energy transfer (FRET) is a powerful approach for identifying biologically relevant molecular interactions with high spatiotemporal resolution. In this study, we described the method of FRET for the measurement of TCR mispairing. It was found that the average FRET efficiency was 12.2 ± 7.5% in HeLa cells and 8.4 ± 3.3% in Jurkat cells (P = 0.026605). The reduction of FRET efficiency in lymphocytes reflected the presence of mispaired TCRs, indicating there were ~30% TCR mispairing in lymphocytes. This study provides a quantitative intracellular assay that can be used to detect TCR mispairing in genetically modified T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20373027     DOI: 10.1007/s11033-010-0053-y

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  33 in total

1.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

2.  Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex.

Authors:  Mirjam H M Heemskerk; Renate S Hagedoorn; Menno A W G van der Hoorn; Lars T van der Veken; Manja Hoogeboom; Michel G D Kester; Roel Willemze; J H Frederik Falkenburg
Journal:  Blood       Date:  2006-09-12       Impact factor: 22.113

3.  Designer T cells by T cell receptor replacement.

Authors:  Daniel Sommermeyer; Julia Neudorfer; Monika Weinhold; Matthias Leisegang; Boris Engels; Elfriede Noessner; Mirjam H M Heemskerk; Jehad Charo; Dolores J Schendel; Thomas Blankenstein; Helga Bernhard; Wolfgang Uckert
Journal:  Eur J Immunol       Date:  2006-11       Impact factor: 5.532

4.  Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.

Authors:  T M Clay; M C Custer; J Sachs; P Hwu; S A Rosenberg; M I Nishimura
Journal:  J Immunol       Date:  1999-07-01       Impact factor: 5.422

5.  Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells.

Authors:  Shao-An Xue; Liquan Gao; Daniel Hart; Roopinder Gillmore; Waseem Qasim; Adrian Thrasher; Jane Apperley; Boris Engels; Wolfgang Uckert; Emma Morris; Hans Stauss
Journal:  Blood       Date:  2005-07-14       Impact factor: 22.113

6.  Targeting self-antigens through allogeneic TCR gene transfer.

Authors:  Moniek A de Witte; Miriam Coccoris; Monika C Wolkers; Marly D van den Boom; Elly M Mesman; Ji-Ying Song; Martin van der Valk; John B A G Haanen; Ton N M Schumacher
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

7.  Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer.

Authors:  Zsolt Sebestyén; Erik Schooten; Tamara Sals; Irene Zaldivar; Esther San José; Balbino Alarcón; Sara Bobisse; Antonio Rosato; János Szöllosi; Jan Willem Gratama; Ralph A Willemsen; Reno Debets
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

8.  Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo.

Authors:  Hollie J Pegram; Jacob T Jackson; Mark J Smyth; Michael H Kershaw; Phillip K Darcy
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

9.  Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain ValphaVbeta fragments.

Authors:  Sarah A Richman; David H Aggen; Michelle L Dossett; David L Donermeyer; Paul M Allen; Philip D Greenberg; David M Kranz
Journal:  Mol Immunol       Date:  2008-10-29       Impact factor: 4.407

Review 10.  Monoclonal T-cell receptors: new reagents for cancer therapy.

Authors:  Hans J Stauss; Michela Cesco-Gaspere; Sharyn Thomas; Daniel P Hart; Shao-An Xue; Angelika Holler; Graham Wright; Mario Perro; Ann-Margaret Little; Constantina Pospori; Judy King; Emma C Morris
Journal:  Mol Ther       Date:  2007-07-17       Impact factor: 11.454

View more
  10 in total

1.  Elucidation of CRISPR-Cas9 application in novel cellular immunotherapy.

Authors:  Sameer Quazi
Journal:  Mol Biol Rep       Date:  2022-02-05       Impact factor: 2.742

2.  Transduction of SIV-specific TCR genes into rhesus macaque CD8+ T cells conveys the ability to suppress SIV replication.

Authors:  Eugene V Barsov; Matthew T Trivett; Jacob T Minang; Haosi Sun; Claes Ohlen; David E Ott
Journal:  PLoS One       Date:  2011-08-23       Impact factor: 3.240

Review 3.  Genetic engineering of T cells for immunotherapy.

Authors:  Gavin I Ellis; Neil C Sheppard; James L Riley
Journal:  Nat Rev Genet       Date:  2021-02-18       Impact factor: 59.581

4.  TCR-engineered T cells: a model of inducible TCR expression to dissect the interrelationship between two TCRs.

Authors:  Simone Reuß; Zsolt Sebestyén; Niels Heinz; Rainer Loew; Christopher Baum; Reno Debets; Wolfgang Uckert
Journal:  Eur J Immunol       Date:  2013-10-20       Impact factor: 5.532

Review 5.  Genome-Edited T Cell Therapies.

Authors:  Juliette M K M Delhove; Waseem Qasim
Journal:  Curr Stem Cell Rep       Date:  2017-04-18

Review 6.  The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses.

Authors:  Diana Campillo-Davo; Donovan Flumens; Eva Lion
Journal:  Cells       Date:  2020-07-18       Impact factor: 6.600

7.  Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing.

Authors:  Diana Campillo-Davo; Fumihiro Fujiki; Johan M J Van den Bergh; Hans De Reu; Evelien L J M Smits; Herman Goossens; Haruo Sugiyama; Eva Lion; Zwi N Berneman; Viggo Van Tendeloo
Journal:  Front Immunol       Date:  2018-11-07       Impact factor: 7.561

Review 8.  Natural killer cells in antitumour adoptive cell immunotherapy.

Authors:  Tamara J Laskowski; Alexander Biederstädt; Katayoun Rezvani
Journal:  Nat Rev Cancer       Date:  2022-07-25       Impact factor: 69.800

Review 9.  Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy.

Authors:  Lukman O Afolabi; Mariam O Afolabi; Musbahu M Sani; Wahab O Okunowo; Dehong Yan; Liang Chen; Yaou Zhang; Xiaochun Wan
Journal:  Clin Transl Immunology       Date:  2021-06-22

10.  Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA.

Authors:  Diana Campillo-Davo; Maarten Versteven; Gils Roex; Hans De Reu; Sanne van der Heijden; Sébastien Anguille; Zwi N Berneman; Viggo F I Van Tendeloo; Eva Lion
Journal:  Cancers (Basel)       Date:  2020-01-21       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.